中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2014年
13期
1993-1994
,共2页
尿激酶型纤溶酶原激活物%颅内栓塞%血栓溶解疗法
尿激酶型纖溶酶原激活物%顱內栓塞%血栓溶解療法
뇨격매형섬용매원격활물%로내전새%혈전용해요법
Urokinase-type plasminogen activator%Intracranial embolism%Thrombolytic therapy
目的 探讨超早期尿激酶静脉溶栓治疗急性脑栓塞的临床疗效及对神经功能缺损的影响.方法 将78例急性脑栓塞患者按照就诊顺序分为两组,每组各39例,对照组采取常规治疗,观察组在对照组基础上加用尿激酶静脉溶栓治疗,比较两组临床治疗效果及患者治疗前后神经功能缺损评分变化.结果 观察组总有效率为92.3％,显著高于对照组的74.4％(x2 =8.332,P＜0.05);观察组治疗后24 h和21 d时美国国立卫生院卒中量表评分分别为(15.63 ±1.78)分和(7.85±1.74)分,明显低于对照组的(19.44±2.05)分和(11.32±1.93)分,两组差异均有统计学意义(t=9.06、9.15,均P＜0.05);两组不良反应发生率差异无统计学意义(x2 =1.002,P＞0.05).结论 超早期尿激酶静脉溶栓治疗急性脑栓塞疗效显著,可较好的减轻患者神经功能缺损,改善患者预后.
目的 探討超早期尿激酶靜脈溶栓治療急性腦栓塞的臨床療效及對神經功能缺損的影響.方法 將78例急性腦栓塞患者按照就診順序分為兩組,每組各39例,對照組採取常規治療,觀察組在對照組基礎上加用尿激酶靜脈溶栓治療,比較兩組臨床治療效果及患者治療前後神經功能缺損評分變化.結果 觀察組總有效率為92.3％,顯著高于對照組的74.4％(x2 =8.332,P＜0.05);觀察組治療後24 h和21 d時美國國立衛生院卒中量錶評分分彆為(15.63 ±1.78)分和(7.85±1.74)分,明顯低于對照組的(19.44±2.05)分和(11.32±1.93)分,兩組差異均有統計學意義(t=9.06、9.15,均P＜0.05);兩組不良反應髮生率差異無統計學意義(x2 =1.002,P＞0.05).結論 超早期尿激酶靜脈溶栓治療急性腦栓塞療效顯著,可較好的減輕患者神經功能缺損,改善患者預後.
목적 탐토초조기뇨격매정맥용전치료급성뇌전새적림상료효급대신경공능결손적영향.방법 장78례급성뇌전새환자안조취진순서분위량조,매조각39례,대조조채취상규치료,관찰조재대조조기출상가용뇨격매정맥용전치료,비교량조림상치료효과급환자치료전후신경공능결손평분변화.결과 관찰조총유효솔위92.3％,현저고우대조조적74.4％(x2 =8.332,P＜0.05);관찰조치료후24 h화21 d시미국국립위생원졸중량표평분분별위(15.63 ±1.78)분화(7.85±1.74)분,명현저우대조조적(19.44±2.05)분화(11.32±1.93)분,량조차이균유통계학의의(t=9.06、9.15,균P＜0.05);량조불량반응발생솔차이무통계학의의(x2 =1.002,P＞0.05).결론 초조기뇨격매정맥용전치료급성뇌전새료효현저,가교호적감경환자신경공능결손,개선환자예후.
Objective To investigate the clinical efficacy of ultra-early intravenous thrombolysis with urokinase for acute cerebral embolism and its effects on neurological impairment.Methods 78 patients with acute cerebral embolism were randomly divided into the two groups according to the order of treatment,and 39 cases in each group.The control group was given conventional treatment,while the observation group was given urokinase thrombolytic therapy.The clinical outcomes and neurological function changes were compared between the two groups.Results The total effective rate of the observation group was 92.3％,which was significantly higher than 74.4％ of the control group (x2 =8.332,P ＜ 0.05).After treatment,the 21 d and 24h NIHSS score of the observation group were (15.63 ± 1.78) points and (7.85 ± 1.74) points,which were significantly lower than (19.44 ± 2.05) points and (11.32 ± 1.93) points of the control group,the differences were statistically significant(t =9.06,9.15,all P ＜ 0.05).There was no significant difference in adverse reactions between the two groups (x2 =1.002,P ＞ 0.05).Conclusion The ultra-early intravenous thrombolysis with urokinase for acute cerebral embolism has significant effect,and it can reduce neurologic impairment,improve clinical outcomes,which is worth to be further promoted and applied in clinical.
